IDO1 and neoplasm: Having confirmed the high concentration of TNFα in bevacizumab-resistant breast cancer and inhibition of TNFα suppressed tumor migration and IDO1 expression in vitro, we treated MDA-MB-231-bearing mice with bevacizumab, anti-TNFα nanobody, both, or PBS.